FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109589973> ?p ?o ?g. }

• W3109589973 endingPage "292" @default.
• W3109589973 startingPage "285" @default.
• W3109589973 abstract "<b><i>Background:</i></b> The addition of tyrosine kinase inhibitors (TKIs) to chemotherapy has dramatically improved outcomes of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). When allogeneic hematopoietic stem cell transplant (HSCT) is performed, maintenance TKI is generally given for a fixed duration. However, the optimal duration of TKI outside of HSCT remains unknown, and the common practice is to continue indefinitely. Here, we report characteristics and outcomes of 9 patients treated with chemotherapy + TKI without HSCT and later discontinued TKI. <b><i>Methods:</i></b> Among 188 patients with Ph-positive ALL who did not undergo HSCT, 9 of them discontinued maintenance TKI mainly due to side effects. Patients were closely monitored with serial PCR testing for the BCR-ABL1 transcript. Major molecular response (MMR) was defined as BCR-ABL1 transcript ≤0.1% on the international scale for p210 transcripts and a 3-log reduction from baseline for p190 transcripts. Deep molecular remission (DMR) was defined as the absence of quantifiable BCR-ABL1 transcripts with a sensitivity of 0.01%. Molecular relapse was defined as loss of MMR. Treatment-free remission (TFR) was defined from time of TKI discontinuation to molecular relapse, last follow-up, or death from any cause. <b><i>Results:</i></b> At the time of TKI discontinuation, transcript level was undetected in 6 patients, &#x3c;0.01% in 2 patients, and 0.01% in another patient. Prior to discontinuation, the median duration of TKI therapy and of DMR was 70 and 47 months, respectively. No morphological relapse occurred. Three patients (33%) had molecular relapse at a median of 6 months. All 3 resumed TKI therapy, and 2 of them regained DMR after a median of 13 months. After a median follow-up of 49 months, the median TFR was not reached, and the 4-year TFR rate was 65%. The median duration of DMR in patients with and without molecular relapse was 22 and 58 months, respectively (<i>p</i> = 0.096). <b><i>Conclusion:</i></b> TKI discontinuation outside of HSCT in Ph-positive ALL in the setting of compelling toxicity may be safe only among a highly selected group of patients with deep and prolonged DMR undergoing close and frequent monitoring. Validation of these findings in prospective clinical trials is highly needed." @default.
• W3109589973 created "2020-12-07" @default.
• W3109589973 creator A5011548707 @default.
• W3109589973 creator A5020340537 @default.
• W3109589973 creator A5022647201 @default.
• W3109589973 creator A5022932599 @default.
• W3109589973 creator A5028845635 @default.
• W3109589973 creator A5029750735 @default.
• W3109589973 creator A5040192170 @default.
• W3109589973 creator A5043585566 @default.
• W3109589973 creator A5049385583 @default.
• W3109589973 creator A5090435894 @default.
• W3109589973 creator A5090618436 @default.
• W3109589973 creator A5091492845 @default.
• W3109589973 date "2020-11-25" @default.
• W3109589973 modified "2023-10-18" @default.
• W3109589973 title "Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant" @default.
• W3109589973 cites W1506738181 @default.
• W3109589973 cites W1838408716 @default.
• W3109589973 cites W1972060994 @default.
• W3109589973 cites W1993808217 @default.
• W3109589973 cites W1996697756 @default.
• W3109589973 cites W2030796837 @default.
• W3109589973 cites W2033862877 @default.
• W3109589973 cites W2045825355 @default.
• W3109589973 cites W2047597898 @default.
• W3109589973 cites W2076165479 @default.
• W3109589973 cites W2096894110 @default.
• W3109589973 cites W2117356576 @default.
• W3109589973 cites W2124174337 @default.
• W3109589973 cites W2139499066 @default.
• W3109589973 cites W2148854558 @default.
• W3109589973 cites W2151029305 @default.
• W3109589973 cites W2163878076 @default.
• W3109589973 cites W2189113171 @default.
• W3109589973 cites W2406225326 @default.
• W3109589973 cites W2424740985 @default.
• W3109589973 cites W2483008971 @default.
• W3109589973 cites W2528188718 @default.
• W3109589973 cites W2599899418 @default.
• W3109589973 cites W2745344769 @default.
• W3109589973 cites W2792113531 @default.
• W3109589973 cites W2793387867 @default.
• W3109589973 cites W2802371729 @default.
• W3109589973 cites W2803250128 @default.
• W3109589973 cites W2806544610 @default.
• W3109589973 cites W2809629567 @default.
• W3109589973 cites W2901346202 @default.
• W3109589973 cites W2902317207 @default.
• W3109589973 cites W2913116303 @default.
• W3109589973 cites W2937713132 @default.
• W3109589973 cites W2985532868 @default.
• W3109589973 cites W2986868459 @default.
• W3109589973 cites W2988562238 @default.
• W3109589973 cites W2990608162 @default.
• W3109589973 doi "https://doi.org/10.1159/000510112" @default.
• W3109589973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33238261" @default.
• W3109589973 hasPublicationYear "2020" @default.
• W3109589973 type Work @default.
• W3109589973 sameAs 3109589973 @default.
• W3109589973 citedByCount "6" @default.
• W3109589973 countsByYear W31095899732022 @default.
• W3109589973 countsByYear W31095899732023 @default.
• W3109589973 crossrefType "journal-article" @default.
• W3109589973 hasAuthorship W3109589973A5011548707 @default.
• W3109589973 hasAuthorship W3109589973A5020340537 @default.
• W3109589973 hasAuthorship W3109589973A5022647201 @default.
• W3109589973 hasAuthorship W3109589973A5022932599 @default.
• W3109589973 hasAuthorship W3109589973A5028845635 @default.
• W3109589973 hasAuthorship W3109589973A5029750735 @default.
• W3109589973 hasAuthorship W3109589973A5040192170 @default.
• W3109589973 hasAuthorship W3109589973A5043585566 @default.
• W3109589973 hasAuthorship W3109589973A5049385583 @default.
• W3109589973 hasAuthorship W3109589973A5090435894 @default.
• W3109589973 hasAuthorship W3109589973A5090618436 @default.
• W3109589973 hasAuthorship W3109589973A5091492845 @default.
• W3109589973 hasConcept C104317684 @default.
• W3109589973 hasConcept C121608353 @default.
• W3109589973 hasConcept C126322002 @default.
• W3109589973 hasConcept C138626823 @default.
• W3109589973 hasConcept C143998085 @default.
• W3109589973 hasConcept C170493617 @default.
• W3109589973 hasConcept C203014093 @default.
• W3109589973 hasConcept C2776694085 @default.
• W3109589973 hasConcept C2777408962 @default.
• W3109589973 hasConcept C2778461978 @default.
• W3109589973 hasConcept C2778715236 @default.
• W3109589973 hasConcept C2778820342 @default.
• W3109589973 hasConcept C2778904597 @default.
• W3109589973 hasConcept C2781107101 @default.
• W3109589973 hasConcept C2909962599 @default.
• W3109589973 hasConcept C2911091166 @default.
• W3109589973 hasConcept C42362537 @default.
• W3109589973 hasConcept C54355233 @default.
• W3109589973 hasConcept C71924100 @default.
• W3109589973 hasConcept C86803240 @default.
• W3109589973 hasConcept C90924648 @default.
• W3109589973 hasConceptScore W3109589973C104317684 @default.

• next